Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2020 · second_quarter · Q2
Value of Prescription Drugs, Senate & House; Issues related to Bayh-Dole Act (Pub. L. 96-517). Issues related to pharmaceutical supply chain, COVID-19 response and health appropriations (no specific bills). Health care issues related to the National Defense Authorization Act (H.R. 2500, S. 1790).
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Source: Senate LDA
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
National Defense Authorization Act for Fiscal Year 2020
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to Bayh-Dole Act (Pub. L. 96-517). Issues related to pharmaceutical supply chain, COVID-19 response and health appropriations (no specific bills). Health care issues related to the National Defense Authorization Act (H.R. 2500, S. 1790).
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Affordable Prescriptions for Patients Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Affordable Prescriptions for Patients Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
National Defense Authorization Act for Fiscal Year 2020
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to Bayh-Dole Act (Pub. L. 96-517). Issues related to pharmaceutical supply chain, COVID-19 response and health appropriations (no specific bills). Health care issues related to the National Defense Authorization Act (H.R. 2500, S. 1790).
Prescription Drug Pricing Reduction Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Prescription Drug Pricing Reduction Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
H.R. 1 - For the People Act of 2019
Lower Costs, More Cures Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019."
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019."
Elijah E. Cummings Lower Drug Costs Now Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019."
Interagency Pandemic Guidance for Consumers Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378).
Affordable Prescriptions for Patients Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Affordable Prescriptions for Patients Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Affordable Prescriptions for Patients Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Accelerated Payments for Small Businesses Act of 2019
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378).
Disclosing Foreign Influence Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Disclosing Foreign Influence Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
Disclosing Foreign Influence Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Disclosing Foreign Influence Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act
Disclosing Foreign Influence Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Disclosing Foreign Influence Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act
Disclosing Foreign Influence Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Disclosing Foreign Influence Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
CLEAN Politics Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
CLEAN Politics Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
Foreign Agents Registration Amendments Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Foreign Agents Registration Amendments Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act
Foreign Agents Registration Amendments Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Foreign Agents Registration Amendments Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
Foreign Agents Registration Amendments Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Foreign Agents Registration Amendments Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Foreign Agents Registration Amendments Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act
Foreign Agents Registration Amendments Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Cancer Drug Parity Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).
Cancer Drug Parity Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).
Cancer Drug Parity Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).
Cancer Drug Parity Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to importation (no specific bills).
Cancer Drug Parity Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).
Protecting Seniors Access to Medicare Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Protecting Seniors Access to Medicare Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Protecting Seniors Access to Medicare Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Protecting Seniors Access to Medicare Act
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Protecting Medicare from Executive Action Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Protecting Medicare from Executive Action Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Protecting Medicare from Executive Action Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Protecting Medicare from Executive Action Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Protecting Seniors' Access to Medicare Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Protecting Seniors' Access to Medicare Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Protecting Seniors' Access to Medicare Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Protecting Seniors' Access to Medicare Act of 2017
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Ensuring Equal Access to Treatments Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Ensuring Equal Access to Treatments Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
Ensuring Equal Access to Treatments Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Ensuring Equal Access to Treatments Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
Cancer Drug Coverage Parity Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Cancer Drug Coverage Parity Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Cancer Drug Coverage Parity Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Cancer Drug Coverage Parity Act of 2015
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Client: ASTELLAS PHARMA US, INC. · Firm: ASTELLAS PHARMA US, INC.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2020 · first_quarter · Q1
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Value of Prescription Drugs, Senate & House; Issues related to Bayh-Dole Act (Pub. L. 96-517).
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019." S.2543 "Prescription Drug Pricing Reduction Act." S. 3129 "Lower Costs, More Cures."
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2019 · fourth_quarter · Q4
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
House and Senate Appropriations for Fiscal Year ending Sept 30, 2019.
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019." H.R.19 "Lower Costs, More Cures Act of 2019."
Value of Prescription Drugs, Senate & House; Issues related to Bayh-Dole Act (Pub. L. 96-517).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2019 · third_quarter · Q3
House and Senate Appropriations for Fiscal Year ending Sept 30, 2019.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues. H.R. 3 "Lower Drug Costs Now Act of 2019."
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2019 · second_quarter · Q2
Biopharmaceutical innovation and patent policy issues; Affordable Prescriptions for Patients Act of 2019 (S.1416).
House and Senate Appropriations for Fiscal Year ending Sept 30, 2019.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2019 · first_quarter · Q1
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378).
Issues related to Medicare Part D policies, including non-interference and rebate policy issues. Drug costs and pricing policy issues. Transparency policy issues.
Biopharmaceutical innovation and patent policy issues.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2018 · fourth_quarter · Q4
House and Senate Appropriations for Fiscal Year ending Sept 30. 2018.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Issues related to Medicare Part D policy (no specific bills).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2018 · third_quarter · Q3
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
Issues related to Medicare Part D policy (no specific bills).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2018 · second_quarter · Q2
House and Senate Appropriations for Fiscal Year ending Sept 30. 2018.
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); PAHPA (S. 2852/H.R. 6378) Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018; REVAMP (H.R. 6294) Re-Valuing Anti-Microbial Products Act of 2018.
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2018 · second_quarter · RA
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2018 · first_quarter · Q1
Issues related to Medicare Part D policy (no specific bills).
Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to importation (no specific bills).
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment; comprehensive tax reform.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2017 · fourth_quarter · Q4
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment; comprehensive tax reform.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2017 · second_quarter · 2A
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment; comprehensive tax reform.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2017 · third_quarter · Q3
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2017 · second_quarter · Q2
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues. S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB) S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2017 · first_quarter · Q1
Issues related to the Medicare hospital outpatient issues; Medicare Part D policy issues.
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment; comprehensive tax reform.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2016 · fourth_quarter · Q4
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2016 · third_quarter · Q3
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment.
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2016 · second_quarter · Q2
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2016 · first_quarter · Q1
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2015 · fourth_quarter · Q4
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2015 · third_quarter · Q3
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2015 · second_quarter · Q2
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6).
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512)
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2015 · first_quarter · Q1
Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.4857, S.2980); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R.4187)
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Cancer Drug Coverage Parity Act (H.R.1801, S.1879).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2014 · fourth_quarter · Q4
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152); Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879).
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152); Issues related to the Medicare hospital outpatient issues (H.R. 4857, S. 2980); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R. 4187)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2014 · third_quarter · Q3
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the Medicare hospital outpatient issues (H.R.4857). Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R. 4187)
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2014 · second_quarter · Q2
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the Medicare hospital outpatient issues (H.R.4857). Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) (H.R. 4187)
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879). Issues related to the Veterans Access to Care Act (H.R. 4810, S. 2450).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2014 · first_quarter · Q1
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, S. 1879).
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the Medicare hospital outpatient proposed rule (no specific bills). Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2014 (DISARM) H.R. 4187
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2013 · fourth_quarter · Q4
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, no specific Senate bill).
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the Medicare hospital outpatient proposed rule (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2013 · third_quarter · Q3
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Cancer Drug Coverage Parity Act (H.R. 1801, no specific Senate bill).
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the Medicare hospital outpatient proposed rule (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2013 · second_quarter · Q2
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2013 · first_quarter · Q1
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to Medicare covering immunosuppressants for ESRD patients post transplant (H.R. 2969).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2012 · fourth_quarter · Q4
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to Medicare covering immunosuppressants for ESRD patients post transplant (H.R. 2969).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2012 · third_quarter · Q3
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to Medicare covering immunosuppressants for ESRD patients post transplant (H.R. 2969).
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734)) Issues related to implementation of the Prescription Drug User Fee Act (now Public Law 112-144)
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2012 · second_quarter · Q2
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to Medicare covering immunosuppressants for ESRD patients post transplant (H.R. 2969).
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (S.3187)
Issues related to the Tariff bills (H.R. 5345; H.R. 5357; H.R. 5358; H.R. 5359; H.R. 5364).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2012 · first_quarter · Q1
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182) (S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to drug shortages (Preserving Access to Life-Saving Medications Act of 2011 (H.R.2245) and Preserving Access to Life-Saving Medications Act (S.296) ); Drug Shortages Prevention Act of 2012 (H.R. 3839))
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2011 · fourth_quarter · Q4
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182/S.1734)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to drug shortages (Preserving Access to Life-Saving Medications Act of 2011 (H.R.2245) and Preserving Access to Life-Saving Medications Act (S.296) )
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2011 · third_quarter · 3A
Issues related to patent reform (the America Invents Act (S.23/H.R. 1249))
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to cancer research and treatment (no specific bills) Issues related to drug safety (no specific bills)
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2011 · third_quarter · Q3
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
Issues related to patent reform (the America Invents Act (S.23/H.R. 1249))
Issues related to the pharmaceutical sales fee and clarification of the orphan drug exemption (no specific bills)
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2011 · second_quarter · Q2
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to the debt ceiling negotiations and Medicare Part D rebates (no specific bills).
Issues related to the pharmaceutical sales fee and clarification of the orphan drug exemption (no specific bills)
Issues related to patent reform (the America Invents Act (S.23/H.R. 1249))
ASTELLAS PHARMA US, INC. via ASTELLAS PHARMA US, INC.
2011 · first_quarter · Q1
Issues related to the pharmaceutical sales fee (no specific bills) Issues related to the renewal of the R&D tax credit (no specific bills)
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (no specific bills) Issues related to the supply of medical isotopes (the American Medical Isotopes Production Act (S.99)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to cancer research and treatment (no specific bills) Issues related to drug safety (no specific bills)
House and Senate Appropriations for Fiscal Year ending Sept 30, 2019.
H.R. 1 - For the People Act of 2019
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act; CLEAN Politics Act of 2018 (H.R. 6533/S. 3274)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
House and Senate Appropriations for Fiscal Year ending Sept 30. 2018.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to Medicare Part D policy (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues and bills related to and affecting the pharmaceutical industry, including those most recently disclosed on the 2018 April Quarterly Report (i.e. Medicare Part D, Bayh-Dole Act, IRC Section 385, H.R.4170, S. 2482, etc.).
H.R. 4170 Disclosing Foreign Influence Act; S. 2482 Foreign Agents Registration Amendments Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to importation (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act of 2017 (H.R.1409); Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517); Issues related to the Prescription Drug User Fee Act (PDUFA) reauthorization; Issues related to importation (no specific bills).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment; comprehensive tax reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment; comprehensive tax reform.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to various patent reform bills (H.R.9, S.632, S.1137).
Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the pharmaceutical sales fee and clarification of the orphan drug exemption (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the pharmaceutical sales fee and clarification of the orphan drug exemption (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to cancer research and treatment (no specific bills) Issues related to drug safety (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152) Issues related to the development of new antibiotics (the Generating Antibiotic Incentives Now Act (H.R. 2182)) Issues related to reauthorization of the Prescription Drug User Fee Act (no specific bills) Issues related to cancer research and treatment (no specific bills) Issues related to drug safety (no specific bills)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152)
Issues related to patent reform (the America Invents Act (S.23/H.R. 1249))
Filing targets: HOUSE OF REPRESENTATIVES, SENATE